

2024

Onco-Nephrology Symposium

SEPTEMBER 13—14, 2024
IN-PERSON / VIRTUAL

ZUCKERMAN RESEARCH CENTER
NEW YORK CITY



CME for
ABPath CC



Memorial Sloan Kettering
Cancer Center

Overview

The 2024 Onco-Nephrology Symposium welcomes all members of the healthcare team who manage patients with both cancer and kidney disease.

This year's program embraces the multidisciplinary nature of onco-nephrology and features experts in plasma cell disorders such as multiple myeloma, amyloidosis, monoclonal gammopathies as well as renowned speakers on CAR T cell, other biologic therapies, thrombotic microangiopathy, and cardio-renal syndromes.

The goal of this forum is to allow academicians, clinicians, and clinical experts to have personal exchanges and robust discussions in order to enhance the clinical experiences and outcomes of patients.

CALL FOR ABSTRACTS

We invite the submission of abstracts relating to clinical care of patients with cancer and kidney disease. The objective is to stimulate discussion on the evaluation and management of kidney injury in patients with cancer. The type of research can be qualitative and/or quantitative and have a focus in basic science, clinical research, public health, or epidemiology. Authors may submit abstracts of completed work or work in progress within the past 12 months.

Abstracts must be submitted by Friday, August 9, 2024.

Educational Objectives

At the conclusion of this program, attendees will be able to:

- Strategize a treatment plan for the patient with MGRS as part of a multidisciplinary team
- Effectively utilize novel diagnostic techniques to diagnose monoclonal disorders
- Formulate an treatment plan for kidney transplant patients who receive CAR T cell therapy
- Outline a comprehensive assessment and treatment of thrombotic microangiopathy
- Assimilate genetic testing data in the evaluation of thrombotic microangiopathy
- Review assessment and management of glomerular disorders in cancer patients
- Apprehend modern therapeutic approaches to small renal masses and cancers of the kidney
- Recognize renal and non renal toxicities of modern cancer therapy

Who Should Attend

The target audience includes physicians, advanced practice providers, nurses, medical students, and other healthcare professionals interested in the care of cancer patients with kidney disease.

Early rates available through July 12, 2024:

msk.org/onco-nephrology

MSK Symposium Directors



Sheron Latcha, MD

Program Director, Nephrology Fellowship;
Attending, Renal Service
Department of Medicine



Aisha Shaikh, MBBS

Associate Attending, Renal Service
Department of Medicine

Invited Faculty

Ala Abudayyeh, MD

Director, of Clinical Research,
Division Section of Nephrology
MD Anderson Cancer Center
Houston, TX, USA

Chris Blosser, MD

Director, Fred Hutch Cancer and
organ Transplant Clinic;
Director, UW Transplant Fellowship
Fred Hutchinson Cancer Center
Seattle, Washington, USA

Sandra Herrmann, MD

Professor of Medicine
Mayo Clinic
Rochester, MN, USA

Kenar Jhaveri, MD

Professor of Medicine;
Co-Director,
Onco-Nephrology Services
Donald and Barbara Zucker School
of Medicine at Hofstra / Northwell
New York, NY, USA

Sabine Karam, MD

Assistant Professor of Medicine
University of Minnesota
Minneapolis, MN, USA

David Kavanagh, PhD

Professor of Complement
Therapeutic at National Renal
Complement Therapeutics Centre
Freeman Hospital Renal Center
Newcastle Upon Tyne, England, UK

Abhijat Kitchlu MD, MSc

Staff Nephrologist;
Clinician Investigator
University Health Network
Associate Professor of Medicine
University of Toronto
Toronto, ON, Canada

Nelson Leung, MD

Professor of Medicine;
Program Director,
Onco-Nephrology Fellowship
Mayo Clinic
Rochester, MN, USA

Syed Saad Mahmood, MD, MPH

System Director, Cardio-Oncology
St. Francis Hospital & Heart Center
Roslyn, NY, USA

Glen Markowitz, MD

Professor of Pathology and
Cell Biology;
Executive Vice Chair for
Anatomic Pathology
Columbia University
Irving Medical Center
New York, NY, USA

Samih Nasr, MD

Professor of Laboratory Medicine
and Pathology
Mayo Clinic
Rochester, MN, USA

Carla Nester, MD, MSA, FASN

Associate Director, Molecular
Otolaryngology and Renal
Research Laboratories;
Director, Pediatric Glomerular
Disease Clinic;
Director, Rare Disease Clinic
University of Iowa Hospitals
and Clinics
Iowa City, IA, USA

MSK Faculty

Lisa Bodei, MD, PhD

Director, Radiopharmaceutical
Therapy Section;
Attending, Molecular Imaging and
Therapy Service
Department of Radiology

Jessica Chapman, PhD

Director, Clinical Proteomics
Assistant Attending,
Hematopathology Service
Department of Pathology and
Laboratory Medicine

Arash Rashidi, MD

Director, Onco-Nephrology
Program
University Hospitals of Cleveland
Westlake, OH, USA

Steven Salvatore, MD

Associate Professor of Clinical
Pathology and Laboratory
Medicine
Weill Cornell Medicine
New York, NY, USA

Biruh Workaneh, MD

Professor of Medicine
MD Anderson Cancer Center
Houston, TX, USA

Sherrilyn Eudoxie, RN

Clinical Nurse

James Flory, MD

Associate Attending,
Endocrinology Service
Department of Medicine;
Associate Professor of Medicine

Samuel Funt, MD

Assistant Attending, Genitoruinary
Oncology Service
Department of Medicine;
Assistant Professor of Medicine

Ilya Glezerman, MD

Attending; Clinical Director,
Renal Service
Department of Medicine

Victoria Gutgarts, MD

Assistant Attending, Renal Service
Department of Medicine;
Assistant Professor of Medicine

Ari Hakimi, MD

Associate Attending,
Urology Service
Department of Surgery;
Associate Professor of Surgery

Hazma Hashimi, MD

Assistant Attending,
Myeloma Service
Department of Medicine

Hani Hassoun, MD

Attending, Myeloma Service
Department of Medicine;
Professor of Medicine

Malin Hulcrantz, MD

Associate Attending,
Myeloma Service
Department of Medicine;
Associate Professor of Medicine

Insara Jaffar, MBBS

Assistant Attending, Renal Service
Department of Medicine;
Assistant Professor of Medicine

Edgar Jaimes, MD

Chief, Renal Service
Department of Medicine;
Professor of Medicine

Heather Landau, MD

Director, Amyloidosis Program;
Associate Attending,
Bone Marrow Transplant and
Cellular Therapy Services
Department of Medicine

Jennifer Liu, MD, FACC

Chief, Cardiology Service;
Director Cardiovascular
Laboratories
Department of Medicine

Monica Maguire, RN

Clinical Nurs

Sham Mailankody, MBBS

Associate Attending;
Clinical Director,
Cellular Therapy Service;
Research Director,
Myeloma Service
Department of Medicine
Associate Professor of Medicine

Kazunori Murata, PhD

Director, Ralph Lauren Center
Laboratory

Karlo Perica, MD

Assistant Attending,
Immunology Program
Sloan Kettering Institute;
Assistant Professor of Medicine

Michael Scordo, MD

Assistant Attending,
Bone Marrow Transplant and
Cellular Therapy Services
Department of Medicine

Saad Usmani, MD

Chief, Myeloma Service
Department of Medicine

Martin Voss, MD

Associate Attending;
Clinical Director, Genitourinary
Medical Oncology Service
Department of Medicine;
Associate Professor of Medicine


Day 1 Schedule

Friday, September 13

- 7:00 AM In-Person Registration and Breakfast
- 7:55 AM Virtual Zoom Sign-on
- 8:00 AM **Introductory Remarks**
Sheron Latcha, MD
Aisha Shaikh, MBBS

This is How We Do It

MODERATOR: Sandra Herrmann, MD

- 8:05 AM  **Department of Medicine Grand Rounds**
How I Treat Monoclonal Gammopathy of Renal Significance (MGRS)
Nelson Leung, MD

- 9:00 AM Break
- 9:15 AM **How I Treat Multiple Myeloma**
Saad Usmani, MD
- 9:40 AM **How I Treat AL Amyloidosis with Kidney Involvement**
Heather Landau, MD
- 10:05 AM **How I Use Serum Free Light Chains in Clinical Practice**
Malin Hulcrantz, MD
- 10:20 AM **Q&A and Panel Discussion**
- 10:30 AM Break

Monoclonal Proteins: Getting to the Heart of the Matter

MODERATOR: Sabine Karam, MD

- 10:45 AM **How I Assess Treatment Response in Plasma Cell Disorders**
Hani Hassoun, MD
- 11:05 AM **Mass Spectrometry Made Simple**
Jessica Chapman, PhD
- 11:20 AM **Newer Methodologies to Detect Monoclonal Proteins in the Blood and Urine in Monoclonal Gammopathy of Renal Significance (MGRS)**
Kazunori Murata, PhD
- 11:35 AM **Newer Methodologies to Detect Monoclonal Proteins on the Kidney Biopsy**
Samih Nasr, MD
- 11:55 AM **Q&A and Panel Discussion**
- 12:05 PM Lunch Break

CAR T Cell Therapy

MODERATOR: Biruh Workaneh, MD

- 1:05 PM **Next Generation Therapy: CARTs and Beyond**
Sham Mailankody, MBBS
- 1:25 PM **CAR T Therapy in Patients with MM and ESRD**
Hazma Hashimi, MD
- 1:45 PM **CAR T Alphabet Soup**
Karlo Perica, MD
- 2:05 PM **Q&A and Panel Discussion**
- 2:15 PM Break
- 2:30 PM **CARs and Solid Organ Transplant**
Chris Blosser, MD
- 2:50 PM **Q&A and Panel Discussion**

Renal and Testicular Cancer

MODERATOR: Kenar Jhaveri, MD

- 2:55 PM **Modern Approach to the Diagnosis and Treatment of Renal Cancer**
Martin Voss, MD
- 3:10 PM **Modern Approach to the Diagnosis and Treatment of Small Renal Masses**
Ari Hakimi, MD
- 3:25 PM **Modern Approach to the Diagnosis and Treatment of Testicular Cancer**
Samuel Funt, MD
- 3:40 PM **Q&A and Panel Discussion**
- 3:50 PM Break

Glomerular and Tubular Matters

MODERATOR: Abhijat Kitchlu MD, MSc

- 4:05 PM **VEGF Inhibitors and TKIs: Stopping and Restarting After Kidney Injury**
Sandra Herrmann, MD
- 4:20 PM **Glomerular Diseases in Chronic GVHD**
Ilya Glezerman, MD
- 4:35 PM **Management of BK Nephropathy Post-SCT**
Ala Abudayyeh, MD
- 4:50 PM **Q&A and Panel Discussion**

5:00 PM **Networking and Poster Reception** (LOBBY)

We invite attendees to a networking reception from 5:00—6:00 PM with hors d'oeuvres and refreshments.

Day 2 Schedule

Saturday, September 14

- 8:00 AM In-Person Registration and Breakfast
- 8:50 AM Virtual Zoom Sign-on
- 8:55 AM **Day 2 Introduction**
Sheron Latcha, MD
Aisha Shaikh, MBBS

Thrombotic Microangiopathy

MODERATOR: Nelson Leung, MD

- 9:00 AM **TMA: Demystifying the Complement Pathway**
Carla Nester, MD, MSA, FASN
- 9:20 AM **Complement Studies and Interpreting Genetic Testing**
David Kavanagh, PhD
- 9:40 AM **Role of Eculizumab and Other Therapies in Non-TA-TMA**
David Kavanagh, PhD
- 10:00 AM **Let's Go to the Data: Eculizumab, Narsoplimab in TA-TMA**
Michael Scordo, MD
- 10:20 AM **Q&A and Panel Discussion**
- 10:30 AM Break

Beyond the Kidneys

MODERATOR: Edgar Jaimes, MD

- 10:45 AM **Diagnosis, Management, and Prognosis of Cardiac Amyloidosis**
Jennifer Liu, MD, FACC
- 11:00 AM **An Update on Radiation Nephropathy — From EBRT to Therapeutic Isotopes**
Lisa Bodei, MD, PhD
- 11:15 AM **Endocrine Toxicities From ICPI**
James Flory, MD
- 11:30 AM **Updates in the Management of Cancer Treatment-Related Cardiac Toxicities**
Syed Saad Mahmood, MD, MPH
- 11:45 AM **Q&A and Panel Discussion**
- 11:55 AM Lunch Break

Case Discussions

1:00 PM	MODERATOR	Arash Rashidi, MD
	PATHOLOGISTS	Steven Salvatore, MD Glen Markowitz, MD
	PANELISTS	Nelson Leung, MD Abhijat Kitchlu, MD, MS Insara Jaffar, MBBS

2:00 PM **Announcement of Poster Winners**

Victoria Gutgarts, MD

2:10 PM **Closing Remarks**

Sheron Latcha, MD
Aisha Shaikh, MBBS

2:20 PM Adjournment

Exclusive Discount Offer

Attendees of the Onco-Nephrology Symposium are eligible a special **\$75 discount** for the **Inaugural Symposium on Kidney Transplantation in Plasma Cell Disorders**, scheduled for the preceding day, Thursday, September 12.



Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **11.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

11.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (**ABIM**) Maintenance of Certification (MOC) program; and

11.00 Lifelong Learning (CME) credits in the American Board of Pathology's (**ABPath**) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.

An application for NCPD credits has been submitted.



Memorial Sloan Kettering
Cancer Center

Early rates available through July 12, 2024:

msk.org/onco-nephrology

Registration Details

This symposium offers participants the choice of attending either in person or virtually.

In-person registrants will be provided continental breakfast, lunch, and refreshment breaks. Contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations for joining us onsite.

Discounted registration is available for specific groups.

Visit the symposium website for additional details:

msk.org/Onco-Nephrology

Symposium Fees

	Early*	General
Physicians (MDs, PhDs, and DOs)	\$400	\$450
Advanced Practice Providers	\$300	\$350
Residents, Fellows, Nurses, and Other Healthcare Providers	\$200	\$250
Industry Professionals**	n/a	\$750
MSK Employees	Complimentary	

*Apply promotion code **ONCNEPH24** during registration to take advantage of early discounted rates. Offer valid through July 12, 2024.

An “industry professional**” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.



Memorial Sloan Kettering
Cancer Center